Literature DB >> 22851144

Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection.

Hadrien Tranchart1, Mircea Chirica, Ailton Sepulveda, Pierre-Philippe Massault, Filomena Conti, Olivier Scatton, Olivier Soubrane.   

Abstract

BACKGROUND: Long-term outcomes of patients who experience recurrence after liver resection (LR) of hepatocellular carcinoma (HCC) are uncertain.
METHODS: The characteristics of 58 patients were obtained from a retrospective database at two time points: primary resection and recurrence. Patterns of recurrence, treatment strategies, and long-term survival rates were analyzed.
RESULTS: The recurrence was inside the Milan criteria (Milan+) in 19 patients (32.7 %), 11 of whom were already eligible for a liver transplant (LT) at the time of primary liver resection (LR). Treatment of the recurrence included the following procedures: salvage LT (n = 6; 10.3 %), repeat LR (n = 7; 12.1 %), percutaneous radiofrequency ablation (RFA) and/or transarterial chemoembolization (TACE) (n = 24; 41.3 %), systemic chemotherapy (n = 15; 25.8 %), and best supportive care (n = 12; 20.7 %). With a mean follow-up of 26.9 ± 27.9 months, the overall 1-, 3-, and 5-year survival rates of the 58 patients with HCC recurrence after primary LR were 57.3, 42.5, and 35.3 %, respectively. In the multivariate analysis the presence of esophageal varices (p = 0.001), an AFP level >200 μg/L (p = 0.03) and a Milan- recurrence pattern (p = 0.05) were independent predictors of decreased survival. The overall 5-year survival of patients who experienced Milan+ recurrence was comparable to that of Milan+ patients who underwent primary LR (62.5 % vs. 66.3 %, p = 0.48).
CONCLUSIONS: Aggressive management of recurrent HCC after upfront LR improves patient survival. The pattern of recurrence is an independent predictor of survival which can be used as a selection criterion for salvage LT.

Entities:  

Mesh:

Year:  2012        PMID: 22851144     DOI: 10.1007/s00268-012-1723-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

1.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

Authors:  Margarita Sala; Josep Fuster; Josep M Llovet; Miquel Navasa; Manel Solé; María Varela; Fernando Pons; Antoni Rimola; Juan Carlos García-Valdecasas; Concepció Brú; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

2.  Repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  N Nagasue; H Kohno; T Hayashi; M Uchida; T Ono; H Yukaya; A Yamanoi
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

3.  Clinical management of recurrent hepatocellular carcinoma.

Authors:  P H Lee; W J Lin; Y M Tsang; R H Hu; J C Sheu; M Y Lai; H C Hsu; W May; C S Lee
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

4.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.

Authors:  J Belghiti; Y Panis; O Farges; J P Benhamou; F Fekete
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

7.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 9.  Repeated liver resection for recurrent liver cancer.

Authors:  N Neeleman; R Andersson
Journal:  Br J Surg       Date:  1996-07       Impact factor: 6.939

10.  One thousand fifty-six hepatectomies without mortality in 8 years.

Authors:  Hiroshi Imamura; Yasuji Seyama; Norihiro Kokudo; Atsushi Maema; Yasuhiko Sugawara; Keiji Sano; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2003-11
View more
  8 in total

Review 1.  [Therapy of hepatocellular carcinoma before liver transplantation].

Authors:  M Guba; M Angele; M Rentsch; K W Jauch; R Zachoval; F Kolligs; A Gerbes; C J Bruns
Journal:  Chirurg       Date:  2013-05       Impact factor: 0.955

2.  Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.

Authors:  Peng S Koh; Albert C Y Chan; Tan T Cheung; Kenneth S H Chok; Wing C Dai; Ronnie T P Poon; Chung M Lo
Journal:  HPB (Oxford)       Date:  2016-01       Impact factor: 3.647

3.  Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC.

Authors:  Zhenhua Hu; Qijun Zhang; Jie Zhou; Zhiwei Li; Jie Xiang; Lin Zhou; Jian Wu; Min Zhang; Shusen Zheng
Journal:  BMJ Open       Date:  2015-09-09       Impact factor: 2.692

4.  Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis.

Authors:  Hao Cai; Wentao Kong; Tie Zhou; Yudong Qiu
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

5.  Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study.

Authors:  Jun Yan; Zhongsong Man; Qian Lu; Kuansheng Ma
Journal:  Cancer Manag Res       Date:  2020-04-17       Impact factor: 3.989

6.  Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma.

Authors:  Huiying Gu; Jing Li; Nan You; Ke Wu; Zheng Wang; Liang Wang; Yinan Zhu; Qinqin Liu; Xuehui Peng; Lu Zheng
Journal:  Ann Transl Med       Date:  2020-12

7.  Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma.

Authors:  Yao Huang; Jianxing Zeng; Teng Liu; Xinju Lin; Pengfei Guo; Jinhua Zeng; Weiping Zhou; Jingfeng Liu
Journal:  Onco Targets Ther       Date:  2020-05-22       Impact factor: 4.147

8.  Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria.

Authors:  Yi-Fu Hou; Bo Li; Yong-Gang Wei; Jia-Yin Yang; Tian-Fu Wen; Ming-Qing Xu; L V-Nan Yan; Ke-Fei Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.